Corbus Pharmaceuticals Holdings Inc
Change company Symbol lookup
Select an option...
CRBP Corbus Pharmaceuticals Holdings Inc
BAC Bank of America Corp
DIS Walt Disney Co
V Visa Inc
UTX United Technologies Corp
UNH UnitedHealth Group Inc
TRV Travelers Companies Inc
PG Procter & Gamble Co
PFE Pfizer Inc

Health Care : Biotechnology | Small Cap GrowthCompany profile

Corbus Pharmaceuticals Holdings, Inc. is a Phase-III, clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The Company operates through developing and commercializing therapeutics to treat rare life-threatening inflammatory fibrotic diseases segment. The Company's lead product candidate, lenabasum, is a novel, synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation and halt fibrotic processes. Lenabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation, and halt fibrosis by activating endogenous pathways. The Company is developing lenabasum to treat four diseases: systemic sclerosis, cystic fibrosis, diffuse cutaneous, skin-predominant dermatomyositis and systemic lupus erythematosus (SLE).

Closing Price
Day's Change
0.22 (4.02%)
B/A Size
Day's High
Day's Low

10-day average volume:



4 providers
June 03, 2019
The one must-know thing that could help marijuana investors

By Nigam Arora Segmented money flows in 17 marijuana stocks reveal investors' views In the runup in marijuana stocks earlier this year, many less-informed investors aggressively bought marijuana stocks near their highs. (MarketWatch)

April 26, 2019
The 'smart' money is telling Canopy Growth investors to be careful

By Nigam Arora Acquiring the rights to buy Acreage Holdings was a clever deal -- but the eventual outcome is uncertain There is more optimism in marijuana stocks after an ingenious deal was revealed. (I will explain that later.) (MarketWatch)

March 28, 2019
UPDATE: Creeping complacency in marijuana-stock investing is a possible warning sign

By Nigam Arora Volatility is down, which more often than not leads to lower stock prices Serious marijuana investors ought to pay attention to the complacency that's creeping into the stock market. Historically when complacency abounds, stocks...(MarketWatch)

March 19, 2019
Corbus Pharmaceuticals started at outperform with $28 stock price target at Oppenheimer

(END) Dow Jones Newswires March 19, 2019 07:24 ET (11:24 GMT) Copyright (c) 2019 Dow Jones & Company, Inc.(MarketWatch)

February 22, 2019
UPDATE: These three marijuana stocks are rising in popularity

By Nigam Arora KushCo Holdings, Curaleaf Holdings and Acreage Holdings are beloved by the momentum crowd, but not by professional investors Marijuana has a bright future, but making money in marijuana is not as simple as buying a few stocks. (MarketWatch)

Earnings Calendar and Events Data provided by |Terms of Use| © 2019 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2019. All rights reserved.